Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
95106 trials found · Page 153 of 4756
-
Could a Half-Dose malaria vaccine be just as good?
⭐️ VACCINE ⭐️ Not yet recruitingThis is a single blind randomised controlled trial (Phase 3 trial). This study aims to assess whether a half-dose of the R21/Matrix-M malaria vaccine is as effective as the full dose in children and adults. The results will help optimize vaccine usage and improve malaria preventi…
Phase: PHASE4 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated May 16, 2026 10:03 UTC
-
Cord blood cells engineered to fight tough lymphoma
Disease control Recruiting nowThis study aims to evaluate the safety and efficacy of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 (TRBC1/2 CAR-NK cells) in patients with refractory or relapsed peripheral T-cell lymphoma (PTCL).
Phase: PHASE1 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated May 16, 2026 10:08 UTC
-
Magic mushroom therapy: do monitors make a difference for depression?
Symptom relief Not yet recruitingPsilocybin, the chemical component of "magic mushrooms", has been administered with psychological support in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. The purpose of this study is to determine the role of psilocybin monitors on…
Phase: PHASE2 • Sponsor: Centre for Addiction and Mental Health • Aim: Symptom relief
Last updated May 16, 2026 10:04 UTC
-
New combo therapy aims to starve liver tumors more effectively
Disease control Recruiting nowTrans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC). TACE is a minimally invasive procedure that involves placing a catheter into the artery in the liver that feeds the tumor, administering chemot…
Phase: PHASE1, PHASE2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Engineered immune cells take on Hard-to-Treat solid tumors
Disease control Not yet recruitingThis Phase 1, open-label, non-randomized study will enroll adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors expressing glypican-3 (GPC3) to examine the safety, feasibility, and efficacy of administering T cell products derived fro…
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
Can a drug stop lung spots from becoming cancer? new trial for smokers.
Prevention Recruiting nowThe main purpose of this study is to assess nadunolimab as an immunoprevention strategy for high-risk lung nodules in participants who are current or former tobacco smokers. The study may last up to 5 years for each participant.
Phase: PHASE2 • Sponsor: Robert Samstein • Aim: Prevention
Last updated May 07, 2026 18:42 UTC
-
New hope for Tough-to-Treat multiple myeloma: IBI3003 trial launches
Disease control Not yet recruitingThis is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 54\~360 subjects, and a phase 2 stage to ex…
Phase: PHASE1, PHASE2 • Sponsor: Fortvita Biologics (USA)Inc. • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug could get bypass patients home days earlier
Symptom relief Not yet recruitingEA-230 is a new therapy that may help people recover faster and have fewer problems after bypass surgery. In an earlier clinical trial, participants who received EA-230 during Coronary Artery Bypass surgery stayed in the Intensive Care Unit (ICU) and the hospital for a shorter ti…
Phase: PHASE3 • Sponsor: EBI Anti Sepsis BV • Aim: Symptom relief
Last updated May 16, 2026 10:07 UTC
-
Could a gut bug boost Crohn's treatment? new trial aims to find out
Disease control Not yet recruitingThis study aims to evaluate whether the combination of Akkermansia muciniphila with infliximab can improve intestinal mucosal healing in patients with Crohn's disease compared with infliximab alone.
Phase: PHASE4 • Sponsor: Chinese Medical Association • Aim: Disease control
Last updated May 06, 2026 16:03 UTC
-
New hope for elderly lymphoma patients: triple-drug combo targets aggressive cancer
Disease control Not yet recruitingThis is a single-arm, prospective, multicenter, open-label phase Ib/II study to evaluate the safety and efficacy of polatuzumab vedotin in combination with rituximab and chidamide in previously untreated elderly patients with MYC/BCL2 double-expressor diffuse large B-cell lymphom…
Phase: PHASE1, PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New study seeks best Post-Surgery strategy for advanced oral cancer
Disease control Not yet recruitingNeoadjuvant immunochemotherapy (NAIC) has demonstrated promising pathological and survival outcomes in patients with resectable locally advanced oral and oropharyngeal squamous cell carcinoma (LA-OSCC/OPSCC). However, the optimal postoperative management strategy following NAIC a…
Sponsor: Zhujiang Hospital • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New drug combo aims to tame rare artery disease
Disease control Not yet recruitingThis is a prospective, open-label, controlled, multiple centers, randonmized clinical trial. It compares the clinical efficacy and safety of vunakizumab ivarmacitinib and glucocorticoids in the treatment of active Takayasu's arteritis.
Phase: PHASE4 • Sponsor: Chinese SLE Treatment And Research Group • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
New drug combo aims to shrink Hard-to-Treat thymic tumors before surgery
Disease control Not yet recruitingThe goal of this clinical trial (Phase II) is to evaluate the efficacy and safety of neoadjuvant Adebrelimab combined with chemoradiation in patients with locally advanced thymic carcinoma. The main questions it aims to answer are: * Is neoadjuvant therapy with Adebrelimab plus …
Phase: PHASE2 • Sponsor: Shanghai Chest Hospital • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Rural china trial aims to stop heart failure before it starts
Prevention Not yet recruitingThe purpose of this study is to prevent heart failure in older adults (aged 65-80 years) living in rural China who have atrial fibrillation but do not currently have heart failure. Because atrial fibrillation significantly increases the risk of developing heart failure , this clu…
Phase: NA • Sponsor: Jiangsu Taizhou People's Hospital • Aim: Prevention
Last updated May 08, 2026 12:04 UTC
-
Immunotherapy combo aims to make liver cancer patients Transplant-Eligible
Disease control Recruiting nowThe investigators are doing this study to learn if a combination of immunotherapy and a liver-directed tumor procedure can safely and effectively shrink or control liver cancer (hepatocellular carcinoma, HCC). The goal is to try to lower the stage of the cancer so that more patie…
Phase: PHASE2 • Sponsor: Ju Dong Yang • Aim: Disease control
Last updated May 16, 2026 10:06 UTC
-
New drug cocktail aims to stop cervical cancer from coming back after surgery
Disease control Not yet recruitingThis study is a single-arm, open-label, multicenter, exploratory clinical trial aimed at observing and evaluating the efficacy and safety of camrelizumab combined with famitinib in the adjuvant treatment of cervical cancer patients after surgery.
Phase: NA • Sponsor: Jin LI • Aim: Disease control
Last updated May 16, 2026 10:07 UTC
-
Triple-Drug attack aims to shrink head and neck tumors
Disease control Not yet recruitingThis is an open-label, randomized, prospective, multicenter phase III trial to evaluate the efficacy and safety of the combination therapy of cetuximab with either pembrolizumab or finotonlimab, alongside chemotherapy, as a first-line treatment, compared with pembrolizumab or fin…
Phase: PHASE3 • Sponsor: Ji Dongmei • Aim: Disease control
Last updated May 07, 2026 18:38 UTC
-
New hope for lymphoma patients: drug may keep cancer in check
Disease control Not yet recruitingThis is a prospective, multicenter, single-arm, open-label phase 2 study designed to evaluate the efficacy and safety of chidamide maintenance in adults with newly diagnosed double-expressor diffuse large B-cell lymphoma (DLBCL) who achieve complete response after induction thera…
Phase: PHASE2 • Sponsor: Rong Tao • Aim: Disease control
Last updated May 16, 2026 10:04 UTC
-
New hope for esophageal cancer patients after standard treatment fails
Disease control Not yet recruitingThe goal of this clinical trial is Iparomlimab and tuvonralimab (QL1706) combined with chemoradiotherapy in the treatment of locally advanced esophageal cancer after failed neoadjuvant chemoimmunotherapy. The main question it aims to answer is: Can it bring survival benefits and …
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New drug could unlock transplants for Hard-to-Match kidney patients
Disease control Not yet recruitingThe goal of this clinical trial is to determine whether belimumab can improve detection of circulating HLA-specific memory B cells to support safer and more effective donor organ allocation in highly sensitized kidney transplant candidates. The main questions it aims to answer a…
Phase: PHASE2 • Sponsor: Leiden University Medical Center • Aim: Disease control
Last updated May 16, 2026 10:07 UTC